BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 04, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analysts picks & changes

Analysts picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/1 cls
Affymetrix (NASDAQ:AFFX) UBS Derik De Bruin Downgrade Buy (from neutral) 10% $8.34
De Bruin lowered his target to $8.50 from $17 after the array company reported earnings below his estimate, and lowered its FY08 revenue guidance to $365-$370M from $400-$420M. He thinks the company’s technology is lagging its peers, and as a result it is losing market share.
Alexion (NASDAQ:ALXN) UBS Jeff Elliott Price target Buy 14% $92.22
Elliott raised his target to $100 from $86 after the company reported 2Q08 earnings and indicated additional launches of Soliris eculizumab are expected this year and next in the EU. He expects strong pricing in the EU and decreased expenses for the remainder of FY08. Elliott raised his FY09 EPS estimate to $2.16 from $1.51. Soliris is marketed to treat paroxysmal nocturnal hemoglobinuria (PNH).
Ambrilia (TSX:AMB) Dundee David Martin Rating change Neutral (from under review) 0% C$0.20
Martin believes the stock may trade down after partner Merck (NYSE:MRK) put a development hold on MK-8122, a phosphorylated prodrug of PPL-100 protease inhibitor (PI) in Phase I testing to treat HIV/AIDS (see BX). But since Merck did not return rights, he thinks there is a chance the PPL-100 program may be restarted. Merck is also exploring potential backup compounds.
Amgen (NASDAQ:AMGN) Baird Christopher Raymond Price target Neutral 16% $62.78
Citigroup Yaron Werber Upgrade Buy (from hold)
Deutsche Bank Mark Schoenebaum Price target Buy
Oppenheimer Bret Holley Price target Market outperform
UBS Maged Shenouda Price target Neutral
Raymond raised his target to $64 from $50 and then again from $64 to $65 after Amgen reported that denosumab met the primary endpoint of a significant decrease in the incidence of new vertebral fractures...

Read the full 2106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >